NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

阿霉素的全球市場

Doxorubicin

出版商 Global Industry Analysts, Inc. 商品編碼 993969
出版日期 內容資訊 英文 215 Pages
商品交期: 最快1-2個工作天內
價格
阿霉素的全球市場 Doxorubicin
出版日期: 2021年05月01日內容資訊: 英文 215 Pages
簡介

全球阿霉素的市場規模,預計在分析期間(2020年∼2027年)將以5.2%的年複合成長率增長,從2020年的10億美元,到2027年達到14億美元。

本報告所分析的市場區隔之一的乳腺癌部門,在分析期間中預計將以5.1%的年複合成長率增長,達到3億3,400萬美元。

本報告提供全球阿霉素市場的相關調查,提供市場佔有率,Covid-19的影響,趨勢和成長要素,各地區的市場分析,競爭情形,主要企業的簡介等資訊。

調查對象企業範例

  • Accord Healthcare
  • Allergan Inc.
  • Baxter International Inc.
  • Cadila Pharmaceuticals
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Johnson & Johnson
  • Meiji Seika Pharma Co.
  • Merrimack Pharmaceuticals Inc.
  • Novartis AG
  • Pfizer Inc.
  • SRS Pharmaceuticals Pvt. Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceuticals
  • Thymoorgan Pharmazie GmbH
  • Zydus Cadila

目錄

I. 調查手法

II. 摘要整理

  • 市場概要
    • 影響者市場洞察
    • 全球市場的軌跡
    • Covid-19的影響與即將到來的全球景氣衰退
  • 主要企業
  • 趨勢與推動要素
  • 全球市場預測

III. 市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 西班牙
  • 俄羅斯
  • 其他歐洲
  • 亞太地區
  • 澳洲
  • 印度
  • 韓國
  • 其他亞太地區
  • 南美
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他南美國家
  • 中東
  • 伊朗
  • 以色列
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 其他中東
  • 非洲

IV. 競爭

  • 企業簡介:42公司

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: MCP21662

Abstract:

Global Doxorubicin Market to Reach US$1.4 Billion by the Year 2027

Amid the COVID-19 crisis, the global market for Doxorubicin estimated at US$992.8 Million in the year 2020, is projected to reach a revised size of US$1.4 Billion by 2027, growing at a CAGR of 5.3% over the analysis period 2020-2027.Breast Cancer, one of the segments analyzed in the report, is projected to grow at a 5.1% CAGR to reach US$313.8 Million by the end of the analysis period.After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Lung Cancer segment is readjusted to a revised 6.9% CAGR for the next 7-year period. This segment currently accounts for a 16.5% share of the global Doxorubicin market.

The U.S. Accounts for Over 40.6% of Global Market Size in 2020, While China is Forecast to Grow at a 7.5% CAGR for the Period of 2020-2027

The Doxorubicin market in the U.S. is estimated at US$402.7 Million in the year 2020. The country currently accounts for a 40.56% share in the global market. China, the world second largest economy, is forecast to reach an estimated market size of US$113.8 Million in the year 2027 trailing a CAGR of 7.5% through 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 3.9% and 5.3% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.3% CAGR while Rest of European market (as defined in the study) will reach US$113.8 Million by the year 2027.

Ovarian Cancer Segment Corners a 14.6% Share in 2020

In the global Ovarian Cancer segment, USA, Canada, Japan, China and Europe will drive the 3.4% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$122.9 Million in the year 2020 will reach a projected size of US$155.6 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$99.6 Million by the year 2027, while Latin America will expand at a 4.2% CAGR through the analysis period.

Select Competitors (Total 59 Featured) -

  • Accord Healthcare
  • Allergan Inc.
  • Baxter International Inc.
  • Cadila Pharmaceuticals
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Johnson & Johnson
  • Meiji Seika Pharma Co.
  • Merrimack Pharmaceuticals Inc.
  • Novartis AG
  • Pfizer Inc.
  • SRS Pharmaceuticals Pvt. Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceuticals
  • Thymoorgan Pharmazie GmbH
  • Zydus Cadila

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Cancer - An Insight
    • Cancer Treatment
    • Chemotherapy: An Overview
    • An Introduction to Doxorubicin - A Chemotherapy Drug
    • Impact of Covid-19 and a Looming Global Recession
    • EXHIBIT 1: World Economic Growth Projections (Real GDP, Annual % Change) for 2020 through 2022
    • COVID-19 Impact on Global Doxorubicin Market
  • GLOBAL MARKET OVERVIEW
    • Global Doxorubicin Market Set to Witness Rapid Growth
    • US Dominates the Doxorubicin Market, Asia-Pacific to Witness Fastest Growth
    • Breast Cancer Constitutes the Largest Application for Doxorubicin
    • Competition
    • New Entrants Seek Opportunities
    • Recent Market Activity
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rise in Cancer Incidence to Drive Market Growth
    • EXHIBIT 2: Breakdown of Total Number of Cancer Cases by Region: 2020
    • EXHIBIT 3: Breakdown of Total Number of Cancer Cases by Type: 2020
    • EXHIBIT 4: Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040
    • Liposomal Delivery Systems Offer Significant Benefits
    • A Review of Liposomal-Doxorubicin Preparations
    • DOX Hydrochloride
    • Ageing Demographics to Drive Demand
    • EXHIBIT 5: Global Aging Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
    • EXHIBIT 6: Elderly Population (65+ Years) as a % of Total Population by Developed, Less Developed and Least Developed Regions: 2019 & 2030
    • Market to Gain from Rise in Number of Breast Cancer Cases
    • Select Doxorubicin Phase IV and Phase III Completed Clinical Trials for Breast Cancer with Results: As of Dec 30, 2019
    • Increasing Prevalence and Incidence of Lung Cancer to Push the Demand for Doxorubicin
    • EXHIBIT 7: Age-Standardized Lung Cancer Rates for Select Countries
    • Lymphoma, Leukemia, Bladder Cancer, & Kaposi Sarcoma: Other Major Growth Areas
    • Uptrend in Healthcare Spending Drives the Doxorubicin Demand
    • EXHIBIT 8: World Healthcare Expenditure (In US$ Billion) for the Years 2017-2023
    • EXHIBIT 9: Healthcare Costs as a % of GDP by Country for the Years 2020 & 2023
    • Cancer Research Spending Continues to Witness Growth
    • EXHIBIT 10: Increasing Share of Cancer Drugs as % Of Total Pharma Drug Pipeline: 2010-2019
    • EXHIBIT 11: NCI Funding for Cancer Research (2002, 2008, 2014 and 2020)
    • A Netherland's Based Research Team Suggests a Variant of Doxorubicin can be Made more Effective without the Heart Damage Side Effect (2020) (The Netherlands)
    • Researchers Develop Non-Toxic and Precise Nanoscale Technology for Oncology Drug Delivery
    • Studies Show Positive Effect of Quantum Dot Enabled Doxorubicin Delivery in Lung Cancer Treatment
    • Innovations in Cancer Drug Delivery: Key Factor in Product Differentiation
    • Peptoid-based Nanotubes Allow Precise, Targeted Delivery of Doxorucibin
    • Combination Therapy: A Double Whammy Success
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Current & Future Analysis for Doxorubicin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 2: World Historic Review for Doxorubicin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 3: World 15-Year Perspective for Doxorubicin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2020 & 2027
    • TABLE 4: World Current & Future Analysis for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 5: World Historic Review for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 6: World 15-Year Perspective for Breast Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 7: World Current & Future Analysis for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 8: World Historic Review for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 9: World 15-Year Perspective for Lung Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 10: World Current & Future Analysis for Ovarian Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 11: World Historic Review for Ovarian Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 12: World 15-Year Perspective for Ovarian Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 13: World Current & Future Analysis for Multiple Myeloma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 14: World Historic Review for Multiple Myeloma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 15: World 15-Year Perspective for Multiple Myeloma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 16: World Current & Future Analysis for Liver Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 17: World Historic Review for Liver Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 18: World 15-Year Perspective for Liver Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 19: World Current & Future Analysis for Leukemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 20: World Historic Review for Leukemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 21: World 15-Year Perspective for Leukemia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 22: World Current & Future Analysis for Kaposi Sarcoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 23: World Historic Review for Kaposi Sarcoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 24: World 15-Year Perspective for Kaposi Sarcoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 25: World Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 26: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 27: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

  • UNITED STATES
    • Market Analysis
    • Rising Cancer Cases Spur Growth in Doxorubicin Market
    • EXHIBIT 12: Estimated Number of New Cancer Cases and Deaths in the US (2019)
    • EXHIBIT 13: Number of FDA-Approved Oncology Drugs in the US (2010-2018)
    • EXHIBIT 14: Number of Cancer Drugs in Development for the Years 2006, 2009, 2012, 2015 and 2018
    • EXHIBIT 15: Cancer Drugs as % of Drug Pipeline in the US for the Period 2010-2019
    • Personalized Medicine Gathers Momentum for Cancer Treatment in the US
    • Market Analytics
    • TABLE 28: USA Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 29: USA Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 30: USA 15-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2012, 2020 & 2027
  • CANADA
    • EXHIBIT 16: Number of New Cancer Cases in Canada: 2019
    • Market Analytics
    • TABLE 31: Canada Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 32: Canada Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 33: Canada 15-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2012, 2020 & 2027
  • JAPAN
    • TABLE 34: Japan Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 35: Japan Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 36: Japan 15-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2012, 2020 & 2027
  • CHINA
    • EXHIBIT 17: Number of New Cancer Cases Diagnosed (in Thousands) in China: 2018
    • Market Analytics
    • TABLE 37: China Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 38: China Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 39: China 15-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2012, 2020 & 2027
  • EUROPE
    • Market Analysis
    • Rising Cancer Incidence and New Drug Development Augur Well for European Cancer Therapies Market
    • EXHIBIT 18: Cancer Incidence in Europe: Number of New Cancer Cases (in Thousands) by Site for 2018
    • EXHIBIT 19: Number of New Cancer Cases Diagnosed (in Thousands) in the UK: 2018
    • Market Analytics
    • TABLE 40: Europe Current & Future Analysis for Doxorubicin by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 41: Europe Historic Review for Doxorubicin by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 42: Europe 15-Year Perspective for Doxorubicin by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2020 & 2027
    • TABLE 43: Europe Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 44: Europe Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 45: Europe 15-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2012, 2020 & 2027
  • FRANCE
    • TABLE 46: France Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 47: France Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 48: France 15-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2012, 2020 & 2027
  • GERMANY
    • TABLE 49: Germany Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 50: Germany Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 51: Germany 15-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2012, 2020 & 2027
  • ITALY
    • TABLE 52: Italy Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 53: Italy Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 54: Italy 15-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2012, 2020 & 2027
  • UNITED KINGDOM
    • TABLE 55: UK Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 56: UK Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 57: UK 15-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2012, 2020 & 2027
  • SPAIN
    • TABLE 58: Spain Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 59: Spain Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 60: Spain 15-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2012, 2020 & 2027
  • RUSSIA
    • TABLE 61: Russia Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 62: Russia Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 63: Russia 15-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2012, 2020 & 2027
  • REST OF EUROPE
    • TABLE 64: Rest of Europe Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 65: Rest of Europe Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 66: Rest of Europe 15-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2012, 2020 & 2027
  • ASIA-PACIFIC
    • Market Analysis
    • An Insight into Asia-Pacific Market for Doxorubicin
    • EXHIBIT 20: Cancer Incidence in Asia: Number of New Cancer Cases (in Thousands) for 2019
    • Market Analytics
    • TABLE 67: Asia-Pacific Current & Future Analysis for Doxorubicin by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 68: Asia-Pacific Historic Review for Doxorubicin by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 69: Asia-Pacific 15-Year Perspective for Doxorubicin by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2020 & 2027
    • TABLE 70: Asia-Pacific Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 71: Asia-Pacific Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 72: Asia-Pacific 15-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2012, 2020 & 2027
  • AUSTRALIA
    • TABLE 73: Australia Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 74: Australia Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 75: Australia 15-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2012, 2020 & 2027
  • INDIA
    • Market Analysis
    • Market Analytics
    • TABLE 76: India Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 77: India Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 78: India 15-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2012, 2020 & 2027
  • SOUTH KOREA
    • TABLE 79: South Korea Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 80: South Korea Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 81: South Korea 15-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2012, 2020 & 2027
  • REST OF ASIA-PACIFIC
    • TABLE 82: Rest of Asia-Pacific Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 83: Rest of Asia-Pacific Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 84: Rest of Asia-Pacific 15-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2012, 2020 & 2027
  • LATIN AMERICA
    • TABLE 85: Latin America Current & Future Analysis for Doxorubicin by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 86: Latin America Historic Review for Doxorubicin by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 87: Latin America 15-Year Perspective for Doxorubicin by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2012, 2020 & 2027
    • TABLE 88: Latin America Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 89: Latin America Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 90: Latin America 15-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2012, 2020 & 2027
  • ARGENTINA
    • TABLE 91: Argentina Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 92: Argentina Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 93: Argentina 15-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2012, 2020 & 2027
  • BRAZIL
    • TABLE 94: Brazil Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 95: Brazil Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 96: Brazil 15-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2012, 2020 & 2027
  • MEXICO
    • TABLE 97: Mexico Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 98: Mexico Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 99: Mexico 15-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2012, 2020 & 2027
  • REST OF LATIN AMERICA
    • TABLE 100: Rest of Latin America Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 101: Rest of Latin America Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 102: Rest of Latin America 15-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2012, 2020 & 2027
  • MIDDLE EAST
    • TABLE 103: Middle East Current & Future Analysis for Doxorubicin by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 104: Middle East Historic Review for Doxorubicin by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 105: Middle East 15-Year Perspective for Doxorubicin by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2012, 2020 & 2027
    • TABLE 106: Middle East Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 107: Middle East Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 108: Middle East 15-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2012, 2020 & 2027
  • IRAN
    • TABLE 109: Iran Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 110: Iran Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 111: Iran 15-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2012, 2020 & 2027
  • ISRAEL
    • TABLE 112: Israel Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 113: Israel Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 114: Israel 15-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2012, 2020 & 2027
  • SAUDI ARABIA
    • TABLE 115: Saudi Arabia Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 116: Saudi Arabia Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 117: Saudi Arabia 15-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2012, 2020 & 2027
  • UNITED ARAB EMIRATES
    • TABLE 118: UAE Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 119: UAE Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 120: UAE 15-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2012, 2020 & 2027
  • REST OF MIDDLE EAST
    • TABLE 121: Rest of Middle East Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 122: Rest of Middle East Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 123: Rest of Middle East 15-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2012, 2020 & 2027
  • AFRICA
    • TABLE 124: Africa Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 125: Africa Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 126: Africa 15-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2012, 2020 & 2027

IV. COMPETITION

  • Total Companies Profiled: 59